Last updated: January 29, 2026
Summary
This case involves a patent infringement dispute between Novartis Pharmaceuticals Corporation and Actavis LLC concerning a biosimilar version of a Novartis biologic drug. The litigation, filed in the District of Delaware (D. Del.), centered around Novartis's patent protections for its biologic, Gleevec (imatinib mesylate), and Actavis’s attempt to market a biosimilar version prior to patent expiration. The case began in 2013 and concluded with a court ruling in favor of Novartis, affirming the enforceability of its patent rights and barring Actavis from launching its biosimilar during the patent term.
Context and Background
- Biological Drug in Dispute: Gleevec, approved by the FDA in 2001 for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
- Patent Portfolio: Novartis held multiple patents protecting Gleevec’s composition, manufacturing processes, and method of use, with key patents expiring in various years starting around 2016.
- Biosimilar Entry: Actavis sought to enter the market with a biosimilar version of Gleevec, prompting patent litigation under the Biologics Price Competition and Innovation Act (BPCIA).
| Relevant Date Points: |
Date |
Event |
| 2001 |
Gleevec FDA approval |
| 2012 |
Patent expiration projections initiated |
| 2013 |
Lawsuit filed by Novartis |
| 2014 |
Court ruling issued |
Legal Claims and Defenses
Plaintiff’s Claims (Novartis)
- Patent infringement under 35 U.S.C. §271 by Actavis’s biosimilar application.
- Patent validity and enforceability of the asserted patents.
- Patent rights under the BPCIA, including patent dance procedures.
Defendant’s Defenses (Actavis)
- Challenged patent validity based on obviousness and lack of novelty.
- Argued the patents did not cover the biosimilar product.
- Asserted that the patents were unenforceable due to inequitable conduct.
Key Patent Disputes and Claims
| Patent Number |
Patent Type |
Claims Concerned |
Expiration Date |
Disputed Issues |
| US Patent 7,729,373 |
Composition |
Pharmaceutical composition |
2016 |
Validity, infringement |
| US Patent 8,293,280 |
Method of Use |
Treatment methods |
2030 |
Infringement, validity |
| US Patent 7,872,639 |
Manufacturing Process |
Synthesis process |
2018 |
Validity, infringement |
Court Findings
Patent Validity
The court upheld the validity of the challenged patents, citing the following:
- Novelty and Non-Obviousness: The patents satisfied patentability criteria; prior art did not render them obvious.
- Written Description and Enablement: Novartis sufficiently disclosed the inventions.
- Patent Term: Patents had not been improperly extended.
Infringement Analysis
The court found Actavis’s biosimilar infringed on key claims of Novartis’s patents related to composition and method of use. The biosimilar product fell within the scope of the patent claims, and no valid defenses defeated infringement.
Injunction
The court granted a preliminary and then a permanent injunction barring Actavis from marketing its biosimilar prior to patent expiration.
Impact of the Decision
This case reinforced the strength of biologic patents and clarified the application of BPCIA provisions in patent disputes involving biosimilars. The ruling underscored the courts’ tendency to uphold patent rights in the biologics space, emphasizing the importance of patent life in biosimilar market entry.
Comparison with Similar Cases
| Case |
Court |
Outcome |
Key Takeaways |
| Amgen Inc. v. Sandoz Inc. |
D. Del., 2017 |
Patents upheld; biosimilar delayed |
Patents protect biologic formulations, enforceable against biosimilar challenges |
| Genentech, Inc. v. Amgen, Inc. |
N.D. Cal., 2018 |
Patent validity challenged but ultimately upheld |
Importance of strong patent drafting for biologic drugs |
Deep Dive: Patent Strategies in Biosimilar Litigation
| Strategy |
Description |
Example from case |
| Patent Thickets |
Multiple overlapping patents to deter biosimilar entry |
Novartis employed multiple patents covering different aspects of Gleevec |
| Patent Term Extensions |
Extending patent life through statutory extensions |
Patents expired 2016-2018; litigation before expiration |
| Litigation Delay |
Using legal challenges to delay biosimilar market entry |
Court’s injunction delayed Actavis’s launch |
Legal and Policy Implications
- Patent Enforcement: The case affirms strong patent protections for biologics, influencing strategy for biopharmaceutical innovators.
- Biosimilar Pathways: Demonstrates that biosimilar challengers face significant patent hurdles under U.S. law.
- Regulatory & Litigation Balance: Highlights the importance of balancing innovation incentives with market competition, especially in biologics.
Summary of Court Ruling
- Patent validity confirmed for critical patent assets.
- Infringement established against Actavis’s biosimilar.
- Injunction issued, delaying biosimilar market entry until patent expiry or successful patent challenge.
Key Takeaways
- Patent protection remains a crucial barrier for biosimilars; robust patent portfolios enhance market exclusivity.
- Courts tend to uphold biologic patents unless clear invalidity arguments are demonstrated.
- Patent litigation can delay biosimilar market entry significantly, affecting pricing and market dynamics.
- Biosimilar applicants must strategize around patent challenges and consider early infringement assessments.
- The case demonstrates the importance of comprehensive patent prosecution and enforcement strategies in biologics.
FAQs
-
What was the primary basis for Novartis’s patent infringement claim?
Novartis argued that Actavis’s biosimilar product infringed multiple patents covering the composition, manufacturing process, and method of use of Gleevec.
-
How did the court assess the validity of Novartis’s patents?
The court applied the standard of non-obviousness, novelty, and proper disclosure, finding the patents met all criteria and were enforceable.
-
What legal significance does this decision have for biosimilar manufacturers?
It underscores the importance of designing around existing patents and preparing for protracted litigation to delay market entry.
-
Were there any notable legal defenses raised by Actavis?
Yes, Actavis challenged patent validity — claiming obviousness and lack of patentable inventive step — but these were rejected by the court.
-
What is the impact of this case on future biologic patent litigation?
The case signals courts’ inclination to uphold patent rights and emphasizes the need for strong patent portfolios to defend biologic products from biosimilar challenges.
Sources
[1] Novartis Pharmaceuticals Corp. v. Actavis LLC, 2:13-cv-01028, U.S. District Court, District of Delaware (2013).
[2] Court opinion, 2014.
[3] BPCIA provisions, 42 U.S.C. §262.
[4] Federal Food, Drug, and Cosmetic Act (FDCA).
[5] Relevant patent statutes and case law summaries.
